Scurry J, et al. - Researchers tested the premise that ERCC1 expression and tumor infiltrating lymphocytes (TILS) are induced by chemotherapy in high grade serous ovarian cancer (HGSOC), which may be useful for assessing prognosis. Participants in the study were 115 HGSOC patients. Compared to the primary cytoreductive surgery group, ERCC1 expression was 2-fold higher in the neoadjuvant chemotherapy group. In HGSOC undergoing neoadjuvant HGSOC treatment ERCC1 could be a possible biomarker for platinum response overall survival.